Eli Lilly’s Zepbound-Taltz combination has delivered strong results in a late-stage clinical trial, showing improved arthritis relief alongside meaningful weight loss, reinforcing the growing link between obesity management and inflammatory dis...
Shilpa Medicare Limited is preparing to seek US approval for its Ondansetron Extended-Release Injection (OERIS) within the next two years and is actively exploring licensing partners. The decision follows a successful Phase 3 trial in India, with..
Granules India announced today that U.S. based company, Granules Pharmaceuticals, Inc., has gotten probable designation of the U.S. Food and Drug Administration (FDA) on its generic amphetamine prolonged discharge pills that treat attention...
Biocon Ltd announced Tuesday that its unit Biocon Biologics oncology biosimilars will expand with three new cancer therapies aimed at strengthening its presence in the global oncology market. With a regulatory filing, the company announced that...
Lupin Ltd announced today that its subsidiary, Lupin Manufacturing Solutions has entered into a longterm agreement with PolyPeptide Group AG. The joint venture will strengthen the global peptide-based active pharmaceutical ingredients supply...
The 3rd Edition of Pack.Nxt successfully concluded on 16 December 2025 at The Lalit, Mumbai, bringing together senior packaging leaders, brand owners, converters, policymakers, consultants, and technology enablers for a full day of honest conversatio
Jaguar Health today announced it has secured a $240,000 FDA grant to advance research on a treatment for chemotherapy-induced diarrhea in dogs, a serious and often dangerous side effect of cancer care...
Strides has made a decisive leadership move to speed up Strides Digital Transformation, appointing Yajuvendra Singh M R as Vice President of Digital Transformation. The appointment, announced today, signals the company’s sharper focus on using...
Semaglutide patent expiry is set to open a Rs 50 billion generic drug opportunity, boosting pharma revenues across India, regulated markets and emerging economies.
Johnson & Johnson completes its $3.05 billion acquisition of Halda Therapeutics, strengthening its oncology pipeline with RIPTAC technology and expanding targeted cancer therapies.
.jpg)
, CDSCO.jpg)